Alliance Pharma Share Discussion Threads

[rivaldo] 23/7/2015 14:09

Nice 94k buy at 53p early this morning, a full 1p above the 52p offer price at the time. Very keen.

[cisk] 22/7/2015 07:30

Comment from Robbie Burns last week will have helped the price no doubt:

Alliance Pharma (APH) looks an interesting pharma with a good pipeline. It didn't have a very good 2014 but statements but recent statements show a much more bullish tone for 2015 and 2016 and the price is rising nicely in response.

Obviously pharmas do carry some risk but I like the risk-reward ratio here and happy to pick some up. It's one of those that could be a massive winner given time. It seems to have a winner in Hydromol performing well.

[capercaillie] 21/7/2015 18:17

Very good run on this - suddenly in play.

[mazarin] 21/7/2015 10:31

I have not seen such positive and sustained 'action' here before without grounds or any news' supportive feed and am equally surprised that no RNS has been issued to indicate change of Interest or Holding.

[norbert colon] 21/7/2015 10:31

This share price action is either Mr Market getting overly excited or APH have lined up another GBP50-100m type deal that I understand was on previously on the cards but never got to the finish line. Such a transformational deal could make 50p look cheap. Guess we will have to wait and see...

[roper] 21/7/2015 09:38

APH now bid as you like at the mid-price. Only 2000 on offer on the rsp. Looks like another leg up is on the cards. GLA

[rivaldo] 20/7/2015 11:17

Good summary Norbert in post 571, nothing to add really.

Buying coming in at 49p now.

[pimpernel4] 15/7/2015 10:18

Whatever it is, there is no denying that there is a buyer about willing to pay current, rising prices - a buyer who clearly recognises value to be unlocked even from these all time high prices.

Congratulations to the company and all patient holders.

[mazarin] 15/7/2015 10:13

Thanks Norbert, I essentially see it the same way and have real expectation that ImmuCyst in particular has the potential to make quite a contribution to the figures when full production resumes. Its sudden loss a few years ago following Sinofi's disaster certainly had a significant impact on APH's profits and it looks like that's behind them now. However I do appreciate that APH has to recover some of its lost market share from competitors who moved in to fill the gap.

[norbert colon] 15/7/2015 08:38

Maz

My thoughts on the price rise / re-rating:

- Seen as a growth share again after last few years malaise
- ImmuCyst coming back on line after a long wait - profitable product
- More deals likely - possibly a big(ger) one
- Possibility of being a bid target themselves

All of that said, the strong re-rating has come as a surprise but thats Mr Market for you - exuberance / depression - repeat.

[mazarin] 14/7/2015 23:40

I believe at 46.5p APH achieved an 'all time high' today. It's certainly the highest since I first bought into it over 16 yrs ago and am really intrigued to know what's currently driving it. I can only assume that there must be some hint of an acquisition somewhere on the horizon or may be it has simply been discovered by a new generation of investors? See a recent comment following pre-close update:

[rivaldo] 14/7/2015 11:30

Cheers hastings.

Here's the Private Punter's article which may generate some further interest:



Conclusion:

"Additional upside potential for Alliance may also be driven by further bolt on acquisitions, where the company has already demonstrated a strong track record.

No less than 26 deals have been completed over a 15 year period, which has resulted in the company delivering improved profitability along with a progressive dividend policy where, with a forecast 1.2p for 2015, it provides an additionally welcome, but modest yield of 2.2%.

For now, broker Numis is anticipating revenues of £48m for next year, rising to £51m by 2017, which could deliver pre-tax profits of £13.1m.

That would see EPS of 3.8p, implying a longer term PER of 11 against the current 13, which suggests decent value in a sector average of close to 16.

There are some notable holders of Alliance's shares, including the respected Nigel Wray, who heads with a 15% stake, while institutions of note are Aviva, Artemis and Slater Investments.

Also of interest is the very recent announcement that the highly experienced Andrew Franklin, who was FD at Genzyme, will be taking up the role of Group FD in September."

[hastings] 13/7/2015 18:28

May be of interest.

[mazarin] 13/7/2015 07:42

For further info on PPRS as mentioned in today's Pre-Close Update see:

[rivaldo] 13/7/2015 07:33

Good, solid trading update today, in line with expectations - and in particular, hinting at more acquisitions to come:

[norbert colon] 10/7/2015 08:19

Riv

Yes I agree. I am also pleased that the appointment is in place as Richard's departure as FD was discussed at the AGM and it was key that they got someone else in quickly to avoid any uncertainty etc. Onward and upward.

[rivaldo] 10/7/2015 07:16

News today. I wouldn't normally comment on the appointment of a new FD, but APH's new FD is certainly worth noting, being the ex-UK FD of Genzyme, and prior to that of Wyeth.

A very impressive appointment for a relative minnow like APH:

[norbert colon] 08/7/2015 14:50

Riv

Yes, that dip to 39p was again another great chance to get on board and the big bounce back up has been surprisingly strong. There is a lot of potential here with acquisitions going forward and I really struggle to ever find something I don't like which I very comforting. I really intend for this to be a long term hold for me and wish us both all the best!

[rivaldo] 08/7/2015 14:30

Norbert, looks like our timeframe may have to be adjusted :o))

[rivaldo] 06/7/2015 07:42

This tip in Money Week hasn't been posted here:



"Alliance Pharma (Aim: APH) is one example of an Aim stock that we think has promise. Its business model is based on picking up established but less well-known drugs that it thinks are undervalued by their companies, with a view to getting the maximum amount of money from them.

It has a portfolio covering over 50 treatments, and specialises in cancer and dermatology drugs. In April it bought MacuVision, which has a successful treatment for macular degeneration, an age-related eye problem.

Despite the fact that Alliance Pharma’s share price has risen by over 20% since we last tipped it in November, it still trades at only 10.3 times forecast 2016 earnings."

[norbert colon] 02/7/2015 10:37

Riv

As a long term shareholder and accumulator on the dips I think you have made a good purchase with a suitable medium / long term timeframe.

[rivaldo] 02/7/2015 08:45

I picked some of these up on the dip at just above 38p, so going pretty well to date.

I liked the look of the company when I saw them present a while back. Should be a nice solid long-termer, with room for sudden jumps in forecasts and the share price on further company or product acquisitions.

[mazarin] 02/7/2015 08:28

Is something 'cooking' here, as there have been a series of steady buy's going through over the last few days that's suggesting someone, somewhere is in the know....? May have some connection to my Post 552

[mazarin] 21/6/2015 08:27

Interactive's comment on Clifford's maiden buy :